Grant: Catalyst Grant: Musculoskeletal Health and Arthritis
University of Ottawa
$100,000.00
The RNA-binding protein Staufen1 as a novel atrogene and therapeutic target in skeletal muscle atrophy
FY 2016-17
Summary
Skeletal muscle atrophy occurs in response to a variety of stressors that include for example, decreases in physical activity and malnutrition. In addition, muscle atrophy is often observed in multiple clinical settings such as in diabetes, cachexia linked to cancer and AIDS, neuromuscular disorders and sarcopenia. Collectively, millions of people in North America suffer from diseases or conditions that cause muscle atrophy, hence posing an enormous socio-economic burden to patients, their families, care givers, and healthcare systems. Such a burden combined with the physical and emotional toll on patients and their families, highlights the urgent need for improved treatment strategies for skeletal muscle atrophy. Our proposal is specifically designed to examine the putative role of a protein called Staufen1 in the events underlying muscle atrophy. These studies are important because they may reveal the potential of Staufen1 as a novel therapeutic target for counteracting muscle atrophy as seen in several diseases and conditions.
Department
Program
Catalyst Grant: Musculoskeletal Health and Arthritis
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
364194
Name
Jasmin Bernard J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
MSK Health - Catalyst Grant IMHA
Projecttitle
The RNA-binding protein Staufen1 as a novel atrogene and therapeutic target in skeletal muscle atrophy
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Musculoskeletal Health and Arthritis
Keyworddelim
Atrogene; Atrophy; Cachexia; Mafbx - Murf1; Neuromuscular Diseases; Phisical Inactivity; Sarcopenia; Skeletal Muscle
Abstract
Skeletal muscle atrophy occurs in response to a variety of stressors that include for example, decreases in physical activity and malnutrition. In addition, muscle atrophy is often observed in multiple clinical settings such as in diabetes, cachexia linked to cancer and AIDS, neuromuscular disorders and sarcopenia. Collectively, millions of people in North America suffer from diseases or conditions that cause muscle atrophy, hence posing an enormous socio-economic burden to patients, their families, care givers, and healthcare systems. Such a burden combined with the physical and emotional toll on patients and their families, highlights the urgent need for improved treatment strategies for skeletal muscle atrophy. Our proposal is specifically designed to examine the putative role of a protein called Staufen1 in the events underlying muscle atrophy. These studies are important because they may reveal the potential of Staufen1 as a novel therapeutic target for counteracting muscle atrophy as seen in several diseases and conditions.
Competitiondate
201701
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jasmin, Bernard J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~